Figure 1.

Relapse kinetics of different AML subtypes and relation to treatment onset.

Relapse kinetics from Ommen and colleagues (several papers) [Ommen et al. 2010, 2014, 2015] and Yin et al. [2012]. Time to treatment onset for azacitidine from Silverman et al. [2011]. Time to treatment onset for chemotherapy and GvL effect based on common clinical observations (disappearance of blasts after first course of chemotherapy, full chimerism often 3 months post transplantation). AML, acute myeloid leukaemia; GvL, graft versus leukaemia.